About CapitalBio

CapitalBio Corporation was established

CapitalBio's electromagnetic biochip was named “one of the top ten scientific and technological advances in China in 2000”

Dr. Jing CHENG, founder of CapitalBio Technology, was the first English monograph on biochips to be published

CapitalBio Technology obtained the first international patent authorization for biochips

EcoScan™-100, China’s first microarray chip scanner based on CCD detection, was introduced.

LuxScan™ 10K, China’s first dedicated laser scanner for microarray chips, was exported to the United States.

"HLA gene chip typing detection service system” is included in the scope of application of the China Bone Marrow Bank’s HLA detection reagents.

ISO9001 and ISO13485 certifications have been obtained.

Nature Biotechnology published self-developed microarray chip papers, and listed CapitalBio Technology as a recommended supplier of global microarray chip products and services.

Affymetrix, the world’s largest gene chip company, formed a strategic partnership.

The self-developed biochip instrument platform won the National Technology Invention Award’s Second Prize

Obtained laboratory accreditation from China National Accreditation Service for Conformity Assessment (CNASL2451)

The State Food and Drug Administration approved the first biochip industry standard developed by CapitalBio Technology

Establishment of the China Hematopoietic Stem Cell Donor Database Sample Bank

CapitalBio Technology became the first Roche NimbleGen certificated service provider in China

 The Genetic Screening Project for hearing impaired disabled people with hereditary deafness in Beijing was complete successfully

CapitalBio Technology’s project to screen for the genes that cause neonatal deafness all over the world was included in the 2012 Beijing Municipal People’s Practical Project.

CapitalBio MedLab was the National Health and Family Planning Commission’s first batch of individualized medical testing pilot units.

 A new generation of high-throughput gene sequencers has been launched

The National Health and Family Planning Commission has approved CapitalBio MedLab as the first batch of clinical pilot units using high-throughput gene detection technology for tumor diagnosis and treatment projects.

Deafness Gene Mutation Detection Kit and LuxScan™ 10K Microarray Chip Scanner obtained Medical Device License in Taiwan.

CapitalBio Technology launched a joint detection product for microRNA and AFP for the early detection of liver cancer.

In clinical trials in the United States, a genetic testing chip for common hereditary deafness in Caucasians obtained phased results.

CapitalBio Technology’s NIPT reached 1.5 million people, preventing the birth of more than 10,000 mentally handicapped children.

CapitalBio Technology’s genetic screening of newborn hereditary deafness has screened over 3.3 million people, directly preventing over 80,000 children and maternal family members from deafness caused by incorrect medication.

The number of people screened in the diabetes management project of CapitalBio Technology Chongqing Liangjiang New District exceeded 100,000, and nearly 10,000 people were diagnosed with diabetes for the first time.

CapitalBio Technology has drafted, promulgated, and implemented a total of 21 national and industry standards.

LeiJingTang, CapitalBio Technology’s Chinese medicine branch, was established in Beijing.

The “Respiratory Pathogens Nucleic Acid Detection Kit (Isothermal Amplification on Disk Chip)” developed by CapitalBio Technology, which includes the COVID-19, was approved for emergency medical devices by the State Food and Drug Administration and received CE-IVD certification

The COVID-19 Mobile Lab developed by CapitalBio Technology, as the first mobile detection bus in China, was put into use.

The SARS-CoV-2 integrated microfluidic chip analysis system, with samples in and results out, was CE-IVD certified.